News Conference News TCT 2025 Ultrathin-Strut DES Performs Well vs Xience in Diabetic Patients: TUXEDO-2 Todd Neale November 03, 2025
News Conference News AHA 2023 ESPRIT: Intensive BP-Lowering Reduces MACE in Chinese Patients Todd Neale November 13, 2023
News Conference News AHA 2023 DAPA-MI: Cardiometabolic Endpoints ‘Win’ With Dapagliflozin After Acute MI Shelley Wood November 11, 2023
News Conference News ACC 2023 Diabetic Patients in Middle East, Africa Overburdened by ASCVD Michael O'Riordan March 14, 2023
News Conference News ACC 2023 Treat to Target or With Intensity? Both Statin Tactics Cut MACE: LODESTAR Michael O'Riordan March 13, 2023
News Conference News ACC 2023 Multifaceted Approach to COORDINATE Diabetes Care Improves GDMT Yael L. Maxwell March 07, 2023
News Conference News ESC 2021 New ESC Prevention Guidelines Focus on Tailored, Escalating Therapy Michael O'Riordan September 03, 2021
News Conference News AHA 2020 No Doctor? No Problem: Remote, Pharmacist-Led Intervention Cuts CVD Risk Michael O'Riordan November 19, 2020
News Conference News ESC 2020 In Long-term, Real-world Data, CABG Bests PCI for Diabetic Patients With MVD Yael L. Maxwell September 01, 2020
News Conference News ESC 2020 EMPEROR-Reduced: Empagliflozin Cuts Hospitalizations, CV Mortality in HFrEF Michael O'Riordan August 28, 2020
News Conference News AHA 2018 Long-term FREEDOM: At Nearly 8 years, CABG Maintains Mortality Benefit Over PCI Michael O'Riordan November 14, 2018
News Conference News ESC 2018 Omega-3 Fatty Acids Fail to Reduce CVD Events in Diabetic Patients: ASCEND Michael O'Riordan August 26, 2018
News Conference News EAS 2018 Glucose and Beyond? Experts Debate Optimal Targets for Managing CV Risk in Diabetics Yael L. Maxwell May 16, 2018
News Conference News ACC 2017 FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo Michael O'Riordan March 17, 2017
News Conference News ESC 2015 ESC Congress 2015: Presentations Sift Clinical Wheat From Chaff September 09, 2015
News Conference News AHA 2014 FACTOR-64: No Benefit to CTA Screening of Asymptomatic Patients with Diabetes November 16, 2014